Your browser doesn't support javascript.
loading
Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans.
Veedfald, Simon; Vedtofte, Louise; Skov-Jeppesen, Kirsa; Deacon, Carolyn F; Hartmann, Bolette; Vilsbøll, Tina; Knop, Filip K; Christensen, Mikkel B; Holst, Jens J.
Afiliación
  • Veedfald S; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Vedtofte L; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • Skov-Jeppesen K; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Deacon CF; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • Hartmann B; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Vilsbøll T; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Knop FK; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • Christensen MB; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Holst JJ; Steno Diabetes Center Copenhagen, Gentofte, Denmark.
J Clin Endocrinol Metab ; 105(3)2020 03 01.
Article en En | MEDLINE | ID: mdl-31665480
ABSTRACT

BACKGROUND:

Glucose-dependent insulinotropic polypeptide (GIP) has been suggested to stimulate the secretion of pancreatic polypeptide (PP), an islet hormone thought to regulate gut motility, appetite, and glycemia.

OBJECTIVE:

To determine whether human GIP1-42 (hGIP) stimulates PP secretion.

METHOD:

As glycemia modulates the secretion of PP, we measured plasma PP concentrations from 2 studies in healthy men (n = 10) and in patients with type 2 diabetes (T2D) (n = 12), where hGIP1-42 had been administered intravenously during fasting glycemia, hyperglycemia (12 mmol/L), and insulin-induced hypoglycemia (targets 2.5 mmol/L [healthy]; 3.5 mmol/L [T2D]). Porcine GIP1-42 (pGIP) was also infused intra-arterially in isolated porcine pancreata (n = 4).

RESULTS:

Mean fasting plasma glucose concentrations were approximately 5 mmol/L (healthy) and approximately 8 mmol/L (T2D). At fasting glycemia, PP concentrations were higher during intravenous hGIP1-42 infusion compared with saline in healthy men (mean [standard error of the mean, SEM], net incremental areas under the curves (iAUCs)[0-30min], 403 [116] vs -6 [57] pmol/L × min; P = 0.004) and in patients with T2D (905 [177] vs -96 [86] pmol/L × min; P = 0.009). During hyperglycemic clamping, mean [SEM] PP concentrations were significantly higher during hGIP1-42 infusion compared with saline in patients with T2D (771 [160] vs -183 [117] pmol/L × min; P = 0.001), but not in healthy individuals (-8 [86] vs -57 [53] pmol/L × min; P = 0.69). When plasma glucose levels were declining in response to exogenous insulin, mean [SEM] PP concentrations were higher during hGIP1-42 infusion compared with saline in healthy individuals (294 [88] vs -82 [53] pmol/L × min; P = 0.0025), but not significantly higher in patients with T2D (586 [314] vs -120 [53]; P = 0.070). At target hypoglycemia, PP levels surged in both groups during both hGIP1-42 and saline infusions. In isolated pancreata, pGIP1-42 increased mean [SEM] PP output in the pancreatic venous effluent (baseline vs infusion, 24[5] vs 79 [16] pmol/min x min; P = 0.044).

CONCLUSION:

GIP1-42 increases plasma PP secretion in healthy individuals, patients with T2D, and isolated porcine pancreata. Hyperglycemia blunts the stimulatory effect of hGIP1-42 in healthy individuals, but not in patients with T2D.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Gastrointestinales / Polipéptido Pancreático / Polipéptido Inhibidor Gástrico / Diabetes Mellitus Tipo 2 / Secreción de Insulina / Hiperglucemia / Hipoglucemia Tipo de estudio: Observational_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Clin Endocrinol Metab Año: 2020 Tipo del documento: Article País de afiliación: Dinamarca

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fármacos Gastrointestinales / Polipéptido Pancreático / Polipéptido Inhibidor Gástrico / Diabetes Mellitus Tipo 2 / Secreción de Insulina / Hiperglucemia / Hipoglucemia Tipo de estudio: Observational_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Clin Endocrinol Metab Año: 2020 Tipo del documento: Article País de afiliación: Dinamarca
...